How Ozempic Stacks Up Against Other GLP-1 Drugs
Ozempic (semaglutide) is a GLP-1 receptor agonist injection approved for type 2 diabetes and chronic weight management. It lowers blood sugar by mimicking GLP-1 hormone, slows gastric emptying, and reduces appetite. Compared to peers, it shows strong weight loss (15-20% body weight over 68 weeks in trials) and A1C reductions (1.5-2%), but differs in dosing, delivery, and approvals.[1]
Ozempic vs. Wegovy: Same Drug, Different Doses and Labels
Wegovy is higher-dose semaglutide (up to 2.4 mg weekly vs. Ozempic's 2 mg max). Wegovy targets weight loss alone, while Ozempic includes diabetes. Wegovy achieves slightly more weight loss (15-17% vs. Ozempic's 12-15% off-label for weight), but shares side effects like nausea. Both from Novo Nordisk; Wegovy faces more supply shortages.[1][2]
Ozempic vs. Mounjaro (Tirzepatide): Dual Agonist Edges Out on Weight Loss
Mounjaro (Eli Lilly) is a GIP/GLP-1 dual agonist. In head-to-head trials like SURPASS, it drops A1C more (2.3% vs. 1.9%) and weight more (22-25 lbs vs. 15-20 lbs over 40-72 weeks) than semaglutide. Mounjaro works faster on appetite suppression but has higher GI side effects. Now branded Zepbound for weight loss.[1][3]
| Drug | Max Weekly Dose | Weight Loss (Avg, 1 Year) | A1C Drop | Cost (Monthly, w/o Insurance) |
|------|-----------------|---------------------------|----------|-------------------------------|
| Ozempic | 2 mg | 15% | 1.8% | $900-1,000 |
| Wegovy | 2.4 mg | 17% | N/A (weight only) | $1,300 |
| Mounjaro/Zepbound | 15 mg | 21% | 2.3% | $1,000-1,100 |
| Trulicity | 4.5 mg | 8-10% | 1.4% | $900 |
Data from clinical trials (e.g., SUSTAIN, SURPASS).[1][3]
Ozempic vs. Trulicity and Other GLP-1s: Dosing and Heart Benefits
Trulicity (dulaglutide, Eli Lilly) is once-weekly like Ozempic but shorter-acting, with less weight loss (5-10%) and A1C drop (1-1.5%). Both reduce cardiovascular events (e.g., 26% risk cut in REWIND for Trulicity, 20% in SUSTAIN-6 for Ozempic). Victoza (liraglutide, daily injection) loses on convenience; Saxenda (higher-dose liraglutide) matches Ozempic weight loss but requires daily shots.[1][2]
Cost and Access: Why Insurance Coverage Varies
Ozempic lists at $936/month; generics absent due to patents (U.S. expiry ~2031-2032).[4] Mounjaro/Zepbound similar, but Medicare covers Ozempic for diabetes—not always weight loss—while Trulicity has broader formulary access. Compounded semaglutide (cheaper, ~$300/month) surged post-shortages but FDA warns of risks like dosing errors.[1][4]
Side Effects and Risks Across the Class
All share nausea (20-40%), vomiting, diarrhea; Ozempic has 1-2% pancreatitis risk, like others. Mounjaro reports more gallbladder issues. Long-term: thyroid tumors in rodents (black-box for all GLP-1s), muscle loss with rapid weight drop. No head-to-head mortality data; CV benefits confirmed for Ozempic, Trulicity.[1][3]
When Patents Expire and Biosimilars Arrive
Novo Nordisk holds semaglutide patents to 2031 (composition) and 2032 (devices); challenges ongoing from Teva, Mylan. First biosimilars likely 2031-2033, dropping prices 30-50% like Humira. Eli Lilly's tirzepatide patents extend to 2036.[4]
[1] NEJM: SUSTAIN trials (semaglutide), https://www.nejm.org/doi/full/10.1056/NEJMoa1901118
[2] Novo Nordisk product labels, https://www.novo-pi.com/ozempic.pdf
[3] SURPASS trials (tirzepatide), https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
[4] DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/OZEMPIC